The Introduction That Wasn't: How a Referral Almost Skipped Regulatory Verification

Signals considered

• regulatory license scope mismatch
• service territory gap
• inventory commitment unconfirmed

Illustrative scenario. This article explains business-signal judgement and human verification. It does not represent a real customer, conversation, contract, revenue result or conversion claim.

This is an illustrative business scenario. It does not describe a specific company, transaction, or real customer.

The situation

A mid-sized orthopedics manufacturer is preparing to enter the Southeast Asian market for the first time. Four weeks before the regulatory filing deadline, the regional sales director forwards an introduction from a well-known local distributor. The email is brief: the distributor has worked with two global brands, covers five major hospital groups, and wants to “discuss exclusive representation as soon as possible.”

The director adds a note: “We need to move on this. They have the hospital access we don’t.”

The channel lead — you in this scenario — receives the introduction with a sense of pressure. The filing window is real. The hospital access claim is compelling. The director is already emotionally invested in this as a fast track.

And that is exactly why the next move cannot be a meeting.

Why this is easy to misread

A distributor introduction looks like progress. It contains keywords that map directly to your market entry checklist: hospital access, brand experience, urgency. But in medical device distribution, none of those keywords substitute for regulatory scope.

Here is what the introduction actually left unstated:

• Device class. Does the distributor’s existing license cover Class II or Class III implants, or only Class I disposables? In many ASEAN regulatory frameworks, a distributor licensed for basic consumables cannot legally hold registration for implantable devices.
• Registration ownership. Does this distributor apply for product registrations under its own license, or does it expect the manufacturer to carry the registration while the distributor serves only as a logistics pass-through? The difference determines liability, audit responsibility, and recall capability.
• License scope. The distributor’s business license may explicitly list approved categories. A “general medical device” line is not the same as “orthopedic implant distributor.”
• Hospital access. “Working with five hospital groups” does not mean the distributor has purchasing contracts or tenders for your category. It may mean they supply gauze to the central supply unit.
• Service capability. Is there a trained clinical support team? A sterile reprocessing arrangement? A complaint handling process aligned with local vigilance requirements?
• Inventory commitment. Does the distributor hold stock, or does every order trigger an import? Emergency replacements and loaner kits require local inventory.
• Compliance record. Have there been prior warning letters, license suspensions, or import holds?

None of these appear in an introductory email. Only one can kill your market entry so quietly that you discover it post-submission.

Evidence to verify

Before a single meeting invitation goes out, the channel lead should collect and review the following minimum evidence for each referred distributor:

1. Current business license with full registered scope — verify device categories, not just “medical.”
2. Product registration history — a list of devices the distributor has registered under its own name in the last three years.
3. License scope match against the specific device class you are entering. A mismatch here is a hard stop.
4. Hospital access evidence — tender awards or purchasing agreements, not anecdotal claims.
5. Service capability documentation — number of field clinical staff, complaint handling SOP, quality management system certificate.
6. Inventory and import records — customs clearance documents showing at least two years of regular medical device imports, ideally in a related category.
7. Compliance letter from the national health authority or a signed declaration of no pending or past sanctions.

This list is a qualification gate, not a due diligence audit. It separates “interesting introduction” from “candidate ready for a deeper review.”

The human next step

After the evidence is collected, the next action is a structured review by a cross-functional team — regulatory, quality, clinical, and commercial — each confirming that their domain requirements are met. One person makes the final recommendation, but no single function unilaterally clears a candidate.

This is where the channel lead owns the process. The director’s urgency is real, but urgency and qualification are different lanes. The channel lead protects both the filing timeline and the quality of the decision by insisting that the gate is met before the meeting is scheduled.

What community messages and introductions cannot prove

No referral email, recommendation call, or message on a professional network can verify identity of the authorized representative, authority to sign a distribution agreement, budget for inventory and regulatory filing fees, compliance standing with the national authority, or final decision-maker alignment between your headquarters and the distributor’s principals.

These must be verified through documentation, cross-checks with the issuing authority, and human confirmation. A conversation builds a relationship. It does not build a qualification file.

The bridge to a repeatable process

The scenario is illustrative, but the pattern is real. Every market entry generates a moment where a promising introduction arrives before the evidence does. The method described here — defining minimum qualification evidence as a gate between introduction and due diligence — works whether you track it in a spreadsheet, a shared drive, or a purpose-built qualification system. The tool is secondary. The discipline of requiring evidence before proceeding is primary.

When that discipline is in place, the channel lead can respond to the next forwarded introduction not with a scheduling link, but with a short evidence request. And that single shift changes everything downstream.

Frequently asked questions

Is it safe to start qualification with a distributor introduction email and a product catalog?

No. An introduction confirms interest and possibly market access, but it does not confirm regulatory license scope, service capability, or compliance history — the three pillars of medical device distribution qualification.

What is the first document to request?

The distributor's current business license with its registered scope. Compare the license scope against the device class you are entering. If the license does not cover your device category, further discussion is premature.